Κλαύδιος Γαληνός
Δωρεάν εγγραφή Αποκτήσετε πρόσβαση σε όλες τις πληροφορίες και τα εργαλεία του Galinos.gr για έναν μήνα
Έλεγχος συγχορήγησης Ελέγξτε την αγωγή σας για αντενδείξεις και αλληλεπιδράσεις μεταξύ των φαρμάκων
Μητρότητα και φάρμακα Ενημερωθείτε για την ασφάλεια χορήγησης ενός φαρμάκου κατά τη διάρκεια της εγκυμοσύνης ή του θηλασμού
Συνδρομές Μάθετε περισσότερα για τα οφέλη και τις επιπλέον παροχές των συνδρομητικών προγραμμάτων
Ενδείξεις και αγωγές Βρείτε θεραπευτικές ενδείξεις και αγωγές για νόσους, συμπτώματα και ιατρικές πράξεις
Γνωρίζατε ότι... Μοιραζόμαστε μαζί σας γεγονότα της πορείας του Galinos.gr από το 2011 μέχρι σήμερα

TOCTINO Capsule, soft (2020)

Αναφορές

Βιβλιογραφική αναφορά

Στοιχεία εκδότη

Εκδότης Stiefel
Διεύθυνση Stockley Park West, , Uxbridge, Middlesex, UB11 1BT , UK
Για την προβολή της πλήρους καταχώρησης απαιτείται συνδρομή σε ισχύ.
Αποκτήστε πρόσβαση σε όλες τις πληροφορίες και τα εργαλεία του Galinos.gr δωρεάν για έναν μήνα απλά κάνοντας εγγραφή.
Δωρεάν εγγραφή

Περιεχόμενα

Name of the medicinal product

Toctino 10 mg capsules, soft. Toctino 30 mg capsules, soft.

Qualitative and quantitative composition

Each capsule, soft contains 10 mg or 30 mg of alitretinoin. Excipients with known effect: Soya-bean oil. Each 10 mg capsule contains 176.50 mg soya-bean oil. Each 30 mg capsule contains 282.40 mg soya-bean ...

Pharmaceutical form

Capsule, soft. The Toctino 10 mg capsule is a brown oval capsule approximately 11 mm in length and 7 mm in width marked with A1. The Toctino 30 mg capsule is a red-brown oval capsule approximately 13 mm ...

Therapeutic indications

Toctino is indicated for use in adults who have severe chronic hand eczema that is unresponsive to treatment with potent topical corticosteroids. Patients in whom the eczema has predominantly hyperkeratotic ...

Posology and method of administration

Toctino should only be prescribed by dermatologists, or physicians with experience in the use of systemic retinoids who have full understanding of the risks of systemic retinoid therapy and monitoring ...

Contraindications

Pregnancy is an absolute contraindication to treatment with Toctino (see section 4.6). Toctino is contraindicated in woman of childbearing potential unless all of the conditions of the Pregnancy Prevention ...

Special warnings and precautions for use

Teratogenic effects Toctino is a powerful human teratogen inducing a high frequency of severe and life threatening birth defects. Toctino is strictly contraindicated in: Pregnant women Women of childbearing ...

Interaction with other medicinal products and other forms of interaction

Pharmacokinetic interaction Alitretinoin is metabolized by cytochrome P450 (CYP) 2C9, CYP2C8, CYP3A4 and undergoes isomerisation. Concomitant medications that may affect the pharmacokinetics of alitretinoin ...

Fertility, pregnancy and lactation

Pregnancy Pregnancy is an absolute contraindication to treatment with Toctino (see section 4.3). If pregnancy does occur in spite of the pregnancy prevention precautions during treatment with Toctino or ...

Effects on ability to drive and use machines

Decreased night vision has been reported in patients treated with alitretinoin and other retinoids. Patients should be advised of this potential problem and warned to be cautious when driving or operating ...

Undesirable effects

The safety and efficacy of Toctino in patients with severe chronic hand eczema (CHE) unresponsive to treatment with potent topical corticosteroids has been evaluated in two randomised, double blind, placebo-controlled ...

Overdose

Alitretinoin is a derivative of vitamin A. Alitretinoin has been administered in oncological clinical studies at dosages of more than 10-times of the therapeutic dosage given for chronic hand eczema. The ...

Pharmacodynamic properties

Pharmacotherapeutic group: other dermatologicals ATC code: D11AH04 Mechanism of action The pharmacological action of retinoids may be explained by their effects on cell proliferation, cell differentiation, ...

Pharmacokinetic properties

Absorption Alitretinoin is a low solubility, low permeability compound with a low and variable bioavailability. Alitretinoin is not consistently absorbed from the gastrointestinal tract in fasted state. ...

Preclinical safety data

Acute toxicity As with other retinoids, the acute toxicity of alitretinoin was low in mice and rats. The LD<sub>50</sub> after intraperitoneal administration was >4000 mg/kg after 24 hours and 1400 mg/kg ...

List of excipients

Capsule content: Soya-bean oil, refined Partially hydrogenated soya-bean oil Triglycerides, medium chain Beeswax, yellow All-rac-α-tocopherol Capsule shell: Gelatin Glycerol Sorbitol, liquid (non-crystallising) ...

Incompatibilities

Not applicable.

Shelf life

3 years.

Special precautions for storage

Do not store above 30°C. Store in the original package. Keep the blister in the outer carton in order to protect from light.

Nature and contents of container

PVC/PE/PVDC/Aluminum blisters. Pack sizes of 30 capsules, soft.

Special precautions for disposal and other handling

Any unused medicinal product or waste material should be disposed in accordance with local requirements.

Marketing authorization holder

GlaxoSmithKline UK Limited, 980 Great West Road, Brentford, Middlesex, TW8 9GS Trading as Stiefel

Marketing authorization number(s)

10mg, 30 capsules PL 19494/0252 30mg, 30 capsules PL 19494/0253

Date of first authorization / renewal of the authorization

Date of first authorisation: 31 May 2013 Date of latest renewal: 30 July 2013

Date of revision of the text

15 June 2020

Πηγαίο έγγραφο

Το πηγαίο έγγραφο για αυτήν την βιβλιογραφική αναφορά είναι διαθέσιμο προς μεταφόρτωση:

Μπορείτε να υποστηρίξετε τον Γαληνό στην αποστολή του να παρέχει δωρεάν έγκυρη πληροφόρηση για κάθε φάρμακο απενεργοποιώντας το Ad Blocker για αυτόν τον ιστότοπο.